Rhythm Pharmaceuticals (RYTM) Intangibles (2021 - 2026)

Rhythm Pharmaceuticals (RYTM) has 6 years of Intangibles data on file, last reported at $5.1 million in Q1 2026.

• On a quarterly basis, Intangibles fell 14.33% year-over-year to $5.1 million in Q1 2026; TTM through Mar 2026 was $5.1 million, a 14.33% decrease from a year earlier, with the FY2025 full-year figure at $5.3 million, down 13.85% from the prior year.
• Intangibles for Q1 2026 stood at $5.1 million, down from $5.3 million in the prior quarter.
• Over the last five years, Intangibles for RYTM reached as high as $8.5 million in Q1 2022 and fell as low as $5.1 million in Q1 2026.
• Historically, Intangibles has averaged $6.8 million across 5 years, with a median of $6.8 million in 2024.
• Across the five-year window, Intangibles soared 70.54% in 2022 and declined 14.33% in 2026, its largest moves.
• Year by year, Intangibles stood at $7.9 million in 2022, then declined by 10.85% to $7.0 million in 2023, then slipped by 12.15% to $6.2 million in 2024, then slipped by 13.85% to $5.3 million in 2025, then declined by 4.0% to $5.1 million in 2026.
• Per Business Quant data, the three most recent Intangibles figures were $5.1 million in Q1 2026, $5.3 million in Q4 2025, and $5.5 million in Q3 2025.